
The US Department of Justice and DEA reclassified some marijuana products from Schedule I to Schedule III under federal drug laws, recognizing medical value and lower risk. Following Trump's executive order, officials announced a June 2026 hearing to decide full reclassification. The change enables marijuana research, eases regulatory burdens for cannabis businesses, and provides physicians better clinical information.